Seer, Inc.
HealthcareNASDAQ:SEER · NASDAQ Global Select
+$0.02 today
Vol 0.10M · Avg 0.33M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $47.3M |
| Short-term Investments | $119.4M |
| Receivables | $4.2M |
| Inventory | $8.1M |
| Other Current | $2.6M |
| Total Current Assets | $181.6M |
| PP&E (Net) | $33.4M |
| Long-term Investments | $52.8M |
| Other Non-current | $4.3M |
| Total Non-current Assets | $90.5M |
| Total Assets | $272.1M |
Analysis
Selected assets total $272.1M for Latest. The largest visible component is Short-term Investments at $119.4M, about 43.9% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $47.3M +16.0% | $40.8M +25.4% | $32.5M -38.9% | $53.2M -77.1% | $232.8M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $138.6M -29.2% | $195.7M -31.0% | $283.7M -22.9% | $368.0M +120.0% | $167.3M | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $5.7M -9.3% | $6.2M -7.3% | $6.7M -4.3% | $7.0M +69.4% | $4.1M | $533.8M | $399.4M | -$1.7B |
| Inventory | $7.8M +4.8% | $7.4M +65.6% | $4.5M -2.9% | $4.6M +11.6% | $4.1M | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $2.2M -32.6% | $3.2M +5.4% | $3.1M +46.9% | $2.1M | $0 | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $201.5M -20.4% | $253.3M -23.4% | $330.5M -24.0% | $435.0M +5.7% | $411.7M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $35.2M -14.8% | $41.4M -12.7% | $47.4M +2.1% | $46.4M +39.7% | $33.2M | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $54.7M -13.3% | $63.1M +11.0% | $56.9M +1002.5% | $5.2M -94.5% | $93.2M | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $4.6M -47.5% | $8.8M +476.2% | $1.5M +10.8% | $1.4M +34.5% | $1.0M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $94.5M -16.5% | $113.3M +7.1% | $105.8M +99.7% | $52.9M -58.5% | $127.4M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $296.1M -19.2% | $366.6M -16.0% | $436.3M -10.6% | $487.9M -9.5% | $539.1M | $13.3B | $11.9B | $10.6B |
| Account Payables | $5.6M +21.4% | $4.6M +237.3% | $1.4M -34.9% | $2.1M -44.5% | $3.8M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $2.6M +11.4% | $2.3M +0.7% | $2.3M | $0 | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 -100.0% | $471.0K -6.0% | $501.0K +49.6% | $335.0K -26.7% | $457.0K | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $341.0K -16.4% | $408.0K +98.1% | $206.0K +54.9% | $133.0K -64.6% | $376.0K | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $7.2M +364.0% | $1.5M -43.4% | $2.7M -57.0% | $6.3M +34.2% | $4.7M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $15.7M +2.4% | $15.3M +15.9% | $13.2M +5.1% | $12.6M -6.3% | $13.4M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $21.1M | $0 | $0 | $0 | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $8.0K -83.3% | $48.0K -73.2% | $179.0K -44.1% | $320.0K -6.2% | $341.0K | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $21.1M -11.0% | $23.7M -9.3% | $26.1M -7.8% | $28.4M +24.4% | $22.8M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $36.8M -5.8% | $39.0M -0.9% | $39.4M -3.8% | $40.9M +13.0% | $36.2M | $14.7B | $3.7B | $9.6B |
| Common Stock | $1.0K +0.0% | $1.0K +0.0% | $1.0K +0.0% | $1.0K +0.0% | $1.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$466.0M -18.8% | -$392.4M -28.3% | -$305.8M -39.3% | -$219.5M -73.5% | -$126.5M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $0 -100.0% | $136.0K +170.8% | -$192.0K +84.7% | -$1.3M -133.4% | -$536.0K | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $725.3M | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $259.3M -20.8% | $327.6M -17.5% | $396.9M -11.2% | $447.0M -11.1% | $502.9M | $9.1B | $7.7B | $3.3B |
| Total Debt | $23.7M -8.9% | $26.0M -8.1% | $28.3M -5.4% | $29.9M +28.1% | $23.3M | $724.2M | $410.6M | $399.4M |
| Net Debt | -$23.6M -59.8% | -$14.8M -248.8% | -$4.2M +81.8% | -$23.3M +88.9% | -$209.5M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Kymera Therapeutics, Inc.
NASDAQ:KYMR
$7.09B
Pharvaris N.V.
NASDAQ:PHVS
$2.15B
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
$1.57B
Nurix Therapeutics, Inc.
NASDAQ:NRIX
$1.47B
Monte Rosa Therapeutics, Inc.
NASDAQ:GLUE
$1.19B
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
$856.09M
Cullinan Therapeutics, Inc.
NASDAQ:CGEM
$841.97M
Sana Biotechnology, Inc.
NASDAQ:SANA
$745.82M
C4 Therapeutics, Inc.
NASDAQ:CCCC
$323.03M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$315.01M
Foghorn Therapeutics Inc.
NASDAQ:FHTX
$245.42M
Shattuck Labs, Inc.
NASDAQ:STTK
$236.64M
Nkarta, Inc.
NASDAQ:NKTX
$204.62M
Quantum-Si incorporated
NASDAQ:QSI
$187.28M
Molecular Partners AG
NASDAQ:MOLN
$154.17M
AN2 Therapeutics, Inc.
NASDAQ:ANTX
$129.89M
PepGen Inc.
NASDAQ:PEPG
$101.68M
MediciNova, Inc.
NASDAQ:MNOV
$60.54M
Generation Bio Co.
GBIO
$35.98M
Anebulo Pharmaceuticals, Inc.
ANEB
$15.91M
HCW Biologics Inc.
HCWB
$2.67M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does SEER have?
Seer, Inc. (SEER) reported $47.28M in cash and equivalents in fiscal 2025.
How much debt does SEER carry?
Seer, Inc. (SEER) reported $23.65M of total debt, with net debt of -$23,633,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.